News

Data presented at SLEEP 2021 from Study 303 suggest that long-term use of lemborexant is well received by patients, who reported that the agent helped them fall asleep and improved total sleep time.

The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.

Hermona Soreq, PhD, discusses the complexities of aducanumab’s FDA approval, her initial reaction to the news, and whether it might be greenlit by other country’s regulators.

An excellent epilepsy outcome was achieved in 66% of cases over a median follow-up of 41 months and was not significantly associated with the type of surgery undergone.

The treatment device from Theranica also demonstrated a positive impact on patients who experienced menstrual cramps or pelvic pain.

The executive director of the LEAD Coalition calls for greater collaboration and support from government and the healthcare community in order to boost health equity.

Here's what is coming soon to NeurologyLive.

The pediatric headache specialist at NYU Langone discussed what physicians should be aware of related to the signs and symptoms associated with pediatric migraine.

Deena Kuruvilla, MD, the medical director of the Westport Headache Institute spoke to the potential of e-TNS in the treatment of migraine overall and which gaps in care that it might fill.

The vice president of Medical Affairs in Migraine at Impel discussed the clinical takeaways from the STOP 301 trial of intranasal DHE and the advantages that the novel formulation might offer patients with migraine.

The calcium, magnesium, potassium, and sodium oxybates oral solution, marketed as Xywav, is currently also under review for the treatment of idiopathic hypersomnia, with an FDA decision expected by August 12, 2021.

Neurology News Network for the week ending June 26, 2021.

We kindly ask you to share 5 minutes of your time with us in order to help us better understand how you use social media and how we can better serve you across different platforms.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 25, 2021.

Eli Lilly plans on submitting a biologics license application for donanemab under the accelerated approval pathway based on data from the phase 2 TRAILBLAZER-ALZ study.

The professor of Molecular Neuroscience at the Edmond and Lily Safra Center for Brain Sciences provided thoughts on the comfortability of prescribing aducanumab knowing its safety profile.

Calli L. Cook, NP, DNP, nurse practitioner, Woodruff School of Nursing, Emory University, detailed her vision for creating change within the neurology field by incorporating advanced practice clinicians.

The decision to grant breakthrough therapy designation was based off the proof-of-concept phase 2b study which explored the impact of lecanemab, formerly BAN2401, on reducing brain amyloid beta and clinical decline.

Mike Hennessy Sr, Chairman and founder, MJH Life Sciences™, offers his perspective on the questions around the origin of COVID-19 and applauds the extensive efforts to produce vaccines.

A significantly higher percentage of patients treated with ublituximab compared to those on teriflunomide achieved no evidence of disease activity status.

The clinical fellow at Massachusetts General Hospital discussed the basis of his study evaluating adult neurology trainees and their familiarity with SUDEP and its risks.

Michael J. Thorpy, MD, director of the Sleep-Wake Disorders Center at Montefiore Medical Center, discussed how telemedicine has factored in the care for patients with sleep disorders throughout the pandemic.

The vice president of Medical Affairs in Migraine at Impel discussed the STOP 301 trial of intranasal DHE and how the safety profile offers a positive for patients who would use the agent on-demand.

Alise Carlson, MD, resident of Cleveland Clinic, details the factors and long-term effects misdiagnosing a patient with multiple sclerosis can have on their quality of life.

At 2 hours after the start of the infusion, headache pain freedom was reported by 23.5% of patients receiving eptinezumab compared to 12% in the placebo group.

The medical director of the Ohio State Sleep Medicine Institute provided insight on areas within sleep disorder care that need improvement, including the diagnostic process.

The duo from Cleveland Clinic addressed several of their research projects presented at AHS 2021 that covered a range of COVID-19 related topics, including the unknowns about associated headaches.

The vice president of Medical Affairs in Migraine at Impel discussed the gaps in care that novel dihydroergotamine formulations, such as INP104, might be able to fill for patients with migraine.

The blood-thinning therapy was approved in both oral pellet and capsule forms for varying pediatric populations.

The exploratory end point of the ability to thrive in symptomatic patients was met by 30% of those in a subanalysis of STR1VE-EU, compared to none in the comparative Preclinical Neuromuscular Clinical Research study.